Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Dana-Farber Cancer Institute34 enrolled

Overview

The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.

Patients will receive temozolomide orally once daily for one week, followed by a one-week rest period. This one-week on/one week off schedule will continue for the duration of treatment unless significant side effects develop. Bevacizumab will be administered intravenously every other week. After eight weeks (two cycles), a CT scan will be performed to see how treatment affected tumor growth. Bactrim, an antibiotic, and acyclovir, an antiviral medicine, will be given in order to help prevent infection. Blood tests will be done every other week to evaluate any side effects. Once the study has been completed, a physical exam, vital signs, blood tests, and CT scan will be performed. Patients will remain on the study as long as they continue to receive benefit from the treatment and there are no serious side effects.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Neuroendocrine Tumors

Interventions

BevacizumabDRUG

Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.

TemozolomideDRUG

Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically documented locally unresectable or metastatic neuroendocrine tumor excluding small cell carcinoma * Measurable disease \> 1cm by spiral computed tomography (CT) or \> 2cm by other radiographic technique * ECOG performance status of 0-2 * Life expectancy of \> 12 weeks * Prior treatment with chemotherapy is allowed * Total bilirubin \< 2.0mg/dl * AST \< 5x upper limit of normal (ULN) * Serum creatinine \< 2.0mg/dl * Absolute neutrophil count \> 1,000/mm3 * Platelets \> 100,000/mm3 * International Normalized Ratio (INR) \< 1.5 Exclusion Criteria: * Prior treatment with temozolomide, decarbazine or bevacizumab * Clinically apparent central nervous system metastases or carcinomatous meningitis * Clinically significant cardiovascular disease * Major surgery, open biopsy, or significant traumatic injury within 28 days * Pregnant or breast-feeding women * Chronic, daily treatment with aspirin or nonsteroidal anti-inflammatory medication * Serious, nonhealing wound, ulcer or bone fracture * Evidence of bleeding diathesis or coagulopathy * History of other disease or metabolic dysfunction

Locations (3)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Dana-Farber Cancer Insitute

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

To assess the response to bevacizumab in combination with temozolomide in patients with metastatic neuroendocrine tumors

Time frame: 2 years

Secondary Outcomes

To assess the time to progression, progression free survival and safety of bevacizumab in combination with temozolomide in this patient population

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.